Clinical Trials

Several clinical trials evaluate 2'-Hydroxy-4'-methylacetophenone across diverse therapeutic domains, including stage I–IV uterine corpus carcinoma, Lynch syndrome, acute kidney injury, contrast-induced nephropathy, clavicle fractures, mitral valve regurgitation, and mental health wellness. Spanning Early Phase 1, Not Applicable, and unspecified trial phases, these studies are sponsored by academic institutions and research cooperatives, including the National Cancer Institute and various university medical centers. Currently, overall trial recruitment statuses are recorded as not yet recruiting, withdrawn, or suspended.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01199250 Not yet recruiting
Lynch Syndrome|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer
Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation
2100-01 --
NCT04598516 Withdrawn
Acute Kidney Injury (Nontraumatic)|Contrast-induced Nephropathy|Renal Insufficiency
Maastricht University Medical Center
2097-11-01 --
NCT05454306 Suspended
Clavicle Fracture
University of Minnesota
2028-01-09 Not Applicable
NCT04795856 Not yet recruiting
Mitral Valve Regurgitation
University of Alabama at Birmingham
2027-06-18 Early Phase 1
NCT06359262 Not yet recruiting
Mental Health Wellness 1
Karolinska Institutet
2027-01-01 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 2'-Hydroxy-4'-methylacetophenone product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

2'-Hydroxy-4'-methylacetophenone acts as an active chemical intermediate and acaricidal agent by interacting with essential biochemical targets, thereby disrupting critical metabolic signaling pathways and compromising cellular integrity. This targeted inhibition leads to severe cellular dysfunction and mortality in target pests, offering therapeutic relevance in pest management as well as potential clinical utility across evaluated conditions such as uterine corpus carcinoma and renal insufficiency.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.